Williams Companies Inc vs State Street SPDR S&P Biotech ETF — how do they compare? Williams Companies Inc trades at $73.43 (market cap $90.70B), while State Street SPDR S&P Biotech ETF trades at $154.43. The key difference: Williams Companies Inc pays a 2.83% dividend while State Street SPDR S&P Biotech ETF pays none, and State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, Williams Companies Inc nearer its low. Which is the better fit depends on your goals.
| WMB | XBI | |
|---|---|---|
Market Cap | $90.70B | — |
Sector | Energy | Broad Market / Factor |
52-Week High | $79.40 | $164.28 |
52-Week Low | $56.51 | $85.16 |
Enterprise Value | $120.08B | — |
Dividend Yield | 2.83% | — |
Signals from Pluang's Aura AI — not financial advice
Williams Companies (WMB) trades at $73.36, showing minimal daily movement with a slight 0.03% decline. The stock demonstrates strong profitability with 23.4% net income margins and 21.95% ROE, though valuation metrics appear elevated with a P/E of 32.53. Recent developments include a $5.34 billion Blackstone-led investment for power innovation projects and potential $5.5 billion Momentum Midstream acquisition, positioning the company for strategic growth in energy infrastructure.
WMB presents a compelling investment case with strong analyst support (79% buy ratings) and $86 consensus price target representing 17% upside. The company's fee-based midstream model provides revenue stability, while recent strategic investments enhance growth prospects. Key risks include commodity price volatility, execution challenges from major acquisitions, and elevated debt levels at 52% of assets.
No Aura AI signal available yet.
Trailing returns across standard periods
Latest headlines on both assets
Williams is a midstream energy company that owns and operates the large Transco and Northwest pipeline systems and associated natural gas gathering, processing, and storage assets. In August 2018, the firm acquired the remaining 26% ownership of its limited partner, Williams Partners.
Read more on WMB →XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →